AbSci acquires Totient

By The Science Advisory Board staff writers

June 14, 2021 -- Synthetic biology firm AbSci has acquired human immune response discovery company Totient. The deal adds antibody and therapeutic target technology to AbSci's range of offerings.

Totient has expertise in identifying human antibodies in patients with different immune responses; it has reconstructed more than 4,500 antibodies from over 50,000 patients, AbSci said. The company hopes to develop natural human antibodies and target antigens using this expertise and to establish training sets for its Denovium Engine deep-learning model.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.